FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment April 12, 2022 First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... April 21, 2022 DeFi Trial: Smart Design and Impressive Results For the Benefit of... September 10, 2022 Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs January 27, 2022 Load more HOT NEWS Cancer clinical trials – learning lessons from the COVID-19 pandemic New Mom Was Told a Lump in Her Breast Was “Built-Up... Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow No Improvement in OS with Adding Palbociclib to Letrozole for the...
